ALEXANDRE, Marie; PRAGUE, Melanie; MCLEAN, Chelsea; BOCKSTAL, Viki; DOUOGUIH, Macaya; THIEBAUT, Rodolphe

doi:10.1038/s41541-023-00767-y

Statistics In System biology and Translational Medicine [SISTM]
Bordeaux population health [BPH]

PRAGUE, Melanie

Statistics In System biology and Translational Medicine [SISTM]
Bordeaux population health [BPH]

MCLEAN, Chelsea

Langue

Article de revue

Ce document a été publié dans

NPJ vaccines. 2023-11-08, vol. 8, n° 1, p. 174

Résumé en anglais

The persistence of the long-term immune response induced by the heterologous Ad26.ZEBOV, MVA-BN-Filo two-dose vaccination regimen against Ebola has been investigated in several clinical trials. Longitudinal data on IgG-binding antibody concentrations were analyzed from 487 participants enrolled in six Phase I and Phase II clinical trials conducted by the EBOVAC1 and EBOVAC2 consortia. A model based on ordinary differential equations describing the dynamics of antibodies and short- and long-lived antibody-secreting cells (ASCs) was used to model the humoral response from 7 days after the second vaccination to a follow-up period of 2 years. Using a population-based approach, we first assessed the robustness of the model, which was originally estimated based on Phase I data, against all data. Then we assessed the longevity of the humoral response and identified factors that influence these dynamics. We estimated a half-life of the long-lived ASC of at least 15 years and found an influence of geographic region, sex, and age on the humoral response dynamics, with longer antibody persistence in Europeans and women and higher production of antibodies in younger participants.< Réduire

URI

https://oskar-bordeaux.fr/handle/20.500.12278/186968

DOI

http://dx.doi.org/10.1038/s41541-023-00767-y

Projet Européen

Horizon 2020 research and innovation programme

Project ANR

Initiative for the creation of a Vaccine Research Institute - ANR-10-LABX-0077

Unités de recherche

Bordeaux Population Health Research Center (BPH) - UMR 1219

Voir/Ouvrir

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola